Clinical trials: Churg-Strauss Syndrome
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome
The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome
The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial…
- Trial name
- NCT07275190
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
EGPA - Eosinophilic Granulomatosis With Polyangiitis
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).
- Trial name
- RACEMATE (NCT06230354)
- Testing
- Tezepelumab
- Where
- 12 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new…
- Conditions
- Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Samter Triad, HES - Hypereosinophilic Syndrome
- Trial name
- PROMETHEos (NCT04538937)
- Testing
- no intervention
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
- Trial name
- CLIPS (NCT06512883)
- Testing
- Benralizumab
- Where
- 15 sites in United States, Brazil and 8 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Benralizumab Effectiveness in EGPA
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting.
- Trial name
- BELONG-EGPA (NCT07815886)
- Testing
- Benralizumab 30 mg/ml
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European EGPA Study Group
Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)
FASENRA Regulatory Postmarketing Surveillance in Korea
As part of a post approval commitment, the MFDS has requested a study to characterize safety in patients who are treated with FASENRA for severe eosinophilic asthma and/or eosinophilic granulomatosis with polyangiitis (EGPA) by…
- Trial name
- FASENRA rPMS (NCT05091333)
- Where
- 5 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
- Trial name
- E-merge (NCT05030155)
- Testing
- Mepolizumab, cyclophosphamide/azathioprine
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults with eosinophilic granulomatosis with polyangiitis (EGPA) in the European real-life setting.
- Trial name
- Mepo LTF (NCT07591753)
- Testing
- Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 591 people
- Sponsor
- European EGPA Study Group
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
This prospective study will assess if 12 months of vitamin D3 (cholecalciferol) supplementation, in patients with AAV (GPA, MPA, and EGPA) who have deficient or insufficient 25(OH)D3 status at enrollment, correlates with improved…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis
- Trial name
- PRAVDA (NCT04280601)
- Testing
- vitamin D
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Christian Pagnoux
Churg-Strauss Syndrome
CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors
To assess the efficacy of systemic corticosteroids alone as first-line treatment of Churg-Strauss syndrome without poor-prognosis factors as defined by the five-factor score (FFS=0), and to compare the efficacy and safety of…
- Trial name
- NCT00399399
- Testing
- azathioprine, cyclophosphamide
- Where
- Switzerland
- Volunteers
- 72 people
- Sponsor
- Hospices Civils de Lyon
Aortitis, Cutaneous Vasculitis
VCRC Tissue Repository
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies.
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis
- Trial name
- NCT02967068
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Wegener's Granulomatosis, Churg-Strauss Syndrome
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis
- Trial name
- NCT00307593
- Testing
- Infliximab, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Wegener's Granulomatosis, Microscopic Polyangiitis
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Vasculitis is group of diseases where inflammation of blood vessels is the common feature. Patients typically present with fever, fatigue, weakness and muscle and joint aches.
- Conditions
- Wegener's Granulomatosis, Microscopic Polyangiitis, Churg Strauss Syndrome, Polyarteritis Nodosa
- Trial name
- DCVAS (NCT01066208)
- Where
- 120 sites in United States, Argentina and 31 more
- Volunteers
- 3,588 people
- Sponsor
- University of Oxford
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Glomerulonephritis Acute
Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated Glomerulonephritis
Urinary CD4+ and CD8+ T lymphocytes may predict renal flares in patients with inactive ANCA-associated vasculitis and thus serve as early non-invasive biomarkers.
- Trial name
- PRE-FLARED (NCT04428398)
- Testing
- Analysis of urine samples with flow cytometry
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or…
- Trial name
- NCT00315380
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO).
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG)
- Trial name
- AAV-PRO (NCT02507024)
- Testing
- Online questionnaire
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Pennsylvania
Churg Strauss Syndrome
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent…
- Trial name
- MATOCSS (NCT00527566)
- Testing
- Mepolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital